CR2 and inflammatory bowel disease: Accordingly, the evidence suggesting the clinical and biological impact of glycome alterations in the preclinical phase of CD21,86 brings to light the prominent impact of glycans and mucosa glycosylation as a putative trigger of health to intestinal inflammation transition with promising clinical applications for IBD prediction and prevention.